Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.
Management will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET, with a live webcast and replay available via the company’s investor website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SION
+5.32%
+5.32%Session close to close
In the May 13 session, SION gained 5.32%, reflecting a notable positive market reaction.
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with how...
Analysis
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with how Sionna’s stock has previously responded to clear clinical milestones such as the Phase 2a enrollment update, while routine conference announcements typically saw modest moves. Investors have recent visibility into cash of $289.9 million and an unused $250,000,000 shelf/ATM structure, which could shape expectations around funding. Sustainability of any sharp upside historically depended on follow‑through from clinical data rather than investor-relations events alone.
Key Figures
Conference time:2:05 p.m. ETNet loss:$26.8 millionPrior-year net loss:$16.5 million+5 more
8 metrics
Conference time2:05 p.m. ETRBC Capital Markets Global Healthcare Conference on May 20, 2026
Net loss$26.8 millionQ1 2026 net loss from 10-Q
Prior-year net loss$16.5 millionQ1 2025 net loss comparison
R&D expenses$19.0 millionQ1 2026 research and development expenses
G&A expenses$10.6 millionQ1 2026 general and administrative costs
Cash & securities$289.9 millionCash, cash equivalents and marketable securities at March 31, 2026
ATM equity program$250.0 millionAt-the-market equity program size disclosed in 10-Q
ATM shelf registration$250,000,000Form S-3ASR shelf capacity with Leerink Partners
Planned presentation at Guggenheim biotech summit focusing on CFTR programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news-driven moves generally aligned with the tone of announcements, including positive reactions to clinical progress and negative reactions around financial updates or select investor events.
Recent Company History
Over the last few months, Sionna has highlighted steady clinical and corporate activity. Completion of enrollment in the PreciSION CF Phase 2a trial of SION-719 on Apr 27, 2026 drew a modestly positive reaction. Multiple conference and investor-event participations in February, March, and April produced mixed but generally modest price moves. Fourth quarter and full-year 2025 results on Mar 2, 2026, which included a higher net loss and increased expenses, coincided with a more pronounced decline of -7.17%. Today’s conference-participation headline fits the pattern of routine investor-relations updates.
Key Terms
at-the-market, form s-3, rule 10b5-1 trading plan, schedule 13g/a, +2 more
6 terms
at-the-marketfinancial
"registered up to $250,000,000 of common stock for sale under an at-the-market sales agreement"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
form s-3regulatory
"The shelf prospectus is an automatic Form S-3 registration that permits one or more offerings"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
rule 10b5-1 trading planregulatory
"shares at prices between $44.58 and $46.22 per share under a pre-arranged Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
schedule 13g/aregulatory
"[SCHEDULE 13G/A] Sionna Therapeutics, Inc. Amended Passive Investment Disclosure"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
schedule 13d/aregulatory
"[SCHEDULE 13D/A] Sionna Therapeutics, Inc. Amended Major Shareholder Report"
A Schedule 13D/A is an amended disclosure filed with regulators by an investor who already reported owning more than 5% of a company’s shares and needs to update their original filing. Think of it as a public status update that tells markets whether the investor’s ownership, plans, or source of funds have changed; such updates matter because they can signal a push for control, major strategic moves, or increased pressure on management, which can affect stock prices.
cftrmedical
"dual-combination trial of SION-451 with two complementary CFTR modulators"
CFTR is a gene that makes a protein acting like a tiny gate in cell membranes to control the flow of salt and water; when the gate works properly it helps keep mucus thin and organs functioning. Investors care because mutations in CFTR drive serious diseases and create demand for diagnostics, drugs and long-term treatment revenue; progress or setbacks in therapies, approvals or patents directly affect company value.
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.
A live webcast can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.
About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
When will Sionna Therapeutics (SION) present at the 2026 RBC Capital Markets Global Healthcare Conference?
Sionna Therapeutics will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET. According to the company, this session is part of the 2026 RBC Capital Markets Global Healthcare Conference.
How can investors access the Sionna Therapeutics (SION) webcast for the 2026 RBC Healthcare Conference?
Investors can access a live webcast of Sionna Therapeutics’ fireside chat in the Investors section of the company’s website. According to Sionna, a replay will be available following the event.
Will a replay be available for Sionna Therapeutics’ (SION) 2026 RBC Capital Markets conference presentation?
Yes, a replay of Sionna Therapeutics’ fireside chat will be available after the event. According to the company, both the live webcast and replay can be accessed via its investor relations website.
What type of company is Sionna Therapeutics (SION) participating in the 2026 RBC Healthcare Conference?
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment. According to the company, it aims to revolutionize the current treatment paradigm for cystic fibrosis (CF).
Where is the investor information page for Sionna Therapeutics (SION) conference webcasts?
Sionna Therapeutics’ investor information, including the 2026 RBC conference webcast, is available at https://investors.sionnatx.com/. According to the company, both live and replay links are provided in the Investors section.
